Reappraisal of recent clinical trials of angiogenic therapy in myocardial ischemia.
We review the clinical trials of angiogenic therapy for myocardial ischemia, focusing on why the results are unsatisfactory in more recent larger and better designed trials. Critical reappraisal of such trials, in view of the pathophysiologic complexity of the angiogenic process at a molecular level, suggests that the strategy of therapies based on a single growth factor protein or gene may not be adequate for optimal therapeutic response.